Week 12: Biomedical Sciences (Ronayne)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/83

encourage image

There's no tags or description

Looks like no tags are added yet.

84 Terms

1
New cards

What are the six classical hallmarks of cancer?

sustained proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion/metastasis

<p>sustained proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion/metastasis</p>
2
New cards

How do angiogenesis and metastasis promote cancer progression?

angiogenesis recruits blood vessels for oxygen/nutrients; metastasis allows cancer cells to spread to distant organs

3
New cards

What are the major organelles involved in cancer and their functions?

Nucleus: DNA storage, chromatin organization, mutation hotspots

Mitochondria: ATP, ROS, intrinsic apoptosis

ER: protein folding, UPR/ER stress

Lysosomes: degradation/autophagy

4
New cards

How do drugs cross cell membranes?

passive diffusion (small, lipophilic drugs) or carrier-mediated transport (drugs resembling endogenous substrates)

5
New cards

How do ABC efflux pumps cause multidrug resistance (MDR), and how can it be overcome?

ABC pumps export drugs, reducing intracellular accumulation. Strategies include efflux inhibitors, combination therapy, and nanoparticle delivery

6
New cards

How do receptor tyrosine kinases (EGFR/HER2) promote cancer proliferation?

ligand binding causes receptor dimerization and activates downstream RAS-RAF-MEK-ERK and PI3K-AKT-mTOR signaling

7
New cards

How do GPCRs and ABC transporters contribute to cancer progression?

GPCRs activate second-messenger signaling cascades, including EGFR signaling; ABC transporters (P-gp) promote drug resistance through efflux

8
New cards

What pathways does EGFR activate, and which drugs target EGFR mutations?

RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways; EGFR TKIs include erlotinib, gefitinib, and osimertinib

9
New cards

What mechanisms cause resistance to EGFR-targeted therapies?

EGFR T790M mutation, downstream RAS mutations, and MET amplification, which bypasses EGFR to maintain proliferative signaling

10
New cards

What is the Warburg effect, and how is mitochondrial metabolism altered in cancer?

cancer cells often increase glycolysis despite oxygen availability, sometimes reducing reliance on mitochondrial OXPHOS

11
New cards

How does the BCL-2 family regulate intrinsic apoptosis?

BCL-2 inhibits pro-apoptotic BAX/BAK. BAX/BAK form mitochondrial pores, releasing cytochrome c and activating caspases. Venetoclax inhibits BCL-2

12
New cards

What are the major sources of ROS, and how do ROS levels affect cancer?

Mitochondrial ETC complexes I/III and NADPH oxidases.

Low ROS promotes signaling/proliferation; excessive ROS causes DNA damage and genomic instability

13
New cards

How can ROS be therapeutically targeted in cancer?

pro-oxidant therapies increase ROS beyond tumor tolerance, while antioxidant inhibition prevents ROS detoxification, promoting cancer cell death

14
New cards

What are the three UPR sensors, and how do they respond to ER stress?

IRE1α → XBP1s (protein folding/ERAD) or JNK/RIDD (apoptosis)

PERK → eIF2α → ATF4 (adaptation)/CHOP (apoptosis)

ATF6 → Golgi cleavage → folding/ERAD

<p>IRE1α → XBP1s (protein folding/ERAD) or JNK/RIDD (apoptosis)</p><p>PERK → eIF2α → ATF4 (adaptation)/CHOP (apoptosis)</p><p>ATF6 → Golgi cleavage → folding/ERAD</p>
15
New cards

How does bortezomib exploit ER stress in multiple myeloma?

it inhibits proteasomal protein degradation, causing misfolded protein accumulation, excessive ER stress, and apoptosis

16
New cards

How does the UPR promote cancer survival under stressful conditions?

it increases protein-folding capacity during hypoxia/nutrient deprivation. Oncogenic changes (BRCA1, TSC, PTEN loss; MYC/RAS activation) alter UPR signaling, survival, and apoptosis

17
New cards

What are the major DNA repair pathways and their functions?

MMR corrects replication mismatches

HR repairs double-strand breaks accurately using BRCA1/2 and RAD51

NHEJ repairs double-strand breaks without a template but is error-prone

18
New cards

What proteins regulate the DNA damage response, and what treatments exploit DNA damage?

ATM, ATR, CHK1/2, and p53 regulate damage responses. PARP inhibitors (olaparib) exploit HR deficiency; platinum agents, nitrogen mustards, and topoisomerase inhibitors damage DNA

19
New cards

Why are BRCA-mutated tumors sensitive to PARP inhibitors?

PARP inhibition prevents single-strand break repair, causing double-strand breaks during replication

BRCA-mutated cells lack effective HR repair, resulting in genomic instability and cell death

<p>PARP inhibition prevents single-strand break repair, causing double-strand breaks during replication</p><p>BRCA-mutated cells lack effective HR repair, resulting in genomic instability and cell death</p>
20
New cards

What determines PARP inhibitor sensitivity and resistance?

HR deficiency increases sensitivity; restored HR repair can cause resistance

Olaparib is used in selected BRCA-mutated/HR-deficient cancers

21
New cards

What mechanisms regulate gene expression in cancer?

RNA polymerases/transcription factors (MYC, p53), mRNA processing, translation initiation (eIFs), and post-translational modifications. HSP90 inhibitors indirectly disrupt protein regulation

22
New cards

What are common post-translational modifications (PTMs), and what do they regulate?

phosphorylation, ubiquitination, acetylation, and methylation regulate protein stability, localization, activity, and protein-protein interactions

23
New cards

How do PTMs regulate p53 activity?

phosphorylation/acetylation promote nuclear localization and transcriptional activity; ubiquitination promotes proteasomal degradation

24
New cards

How do oncogenes differ from tumor suppressors?

oncogenes gain function to promote growth (RAS, MYC, BCR-ABL); tumor suppressors lose function, removing growth restraints or DNA repair (TP53, RB1, BRCA)

25
New cards

How are oncogenes and tumor suppressors targeted therapeutically?

oncogenes may be directly inhibited (e.g., BCR-ABL); tumor suppressor loss may be exploited through synthetic lethality or targeting associated pathways

26
New cards

How do 5-FU, capecitabine, and methotrexate inhibit cancer proliferation?

They disrupt nucleotide synthesis/DNA replication, primarily affecting S phase. Resistance may involve increased target enzymes or drug metabolism

27
New cards

What occurs during each cell-cycle phase, and which proteins regulate checkpoints?

G1: growth/preparation

S: DNA replication

G2: mitotic preparation

M: division

Cyclins D/E/A/B activate CDKs

p53, Rb, and p21 regulate checkpoints

28
New cards

Which cyclin-CDK complexes regulate cell-cycle progression?

Cyclin D-CDK4/6: G1

cyclin E-CDK2: G1/S

cyclin A-CDK2/CDK1: S/G2

cyclin B-CDK1: mitosis

APC/C promotes mitotic exit

<p>Cyclin D-CDK4/6: G1</p><p>cyclin E-CDK2: G1/S</p><p>cyclin A-CDK2/CDK1: S/G2</p><p>cyclin B-CDK1: mitosis</p><p>APC/C promotes mitotic exit</p>
29
New cards

What cell-cycle abnormalities commonly occur in cancer?

p53 mutations, Rb inactivation, and cyclin D overexpression cause uncontrolled proliferation and genomic instability; Ki-67 reflects proliferation

30
New cards

How do CDK4/6 inhibitors work, and what are their clinical uses and toxicities?

Palbociclib, ribociclib, and abemaciclib block G1 → S progression in HR+/HER2− breast cancer

Toxicities: myelosuppression, hepatotoxicity, and GI effects

31
New cards

How do taxanes and vinca alkaloids differ?

Taxanes (paclitaxel) stabilize microtubules and prevent depolymerization; vinca alkaloids (vincristine) inhibit polymerization

Both cause mitotic arrest

32
New cards

How do topoisomerase I and II inhibitors differ?

Topo I inhibitors (irinotecan) stabilize single-strand breaks; Topo II inhibitors (etoposide, anthracyclines) stabilize double-strand breaks, causing DNA damage/apoptosis. Anthracyclines can cause cardiotoxicity.

33
New cards

What are the major programmed cell-death pathways and their mediators?

Intrinsic apoptosis (mitochondria/BCL-2), extrinsic apoptosis (death receptors), necroptosis (RIPK1/3, MLKL), and ferroptosis (iron/lipid oxidation). Caspases execute apoptosis

34
New cards

How do pro- and anti-apoptotic BCL-2 proteins regulate mitochondrial apoptosis?

BAX/BAK form pores for cytochrome c release; BCL-2/BCL-XL inhibit them

BH3 mimetics (venetoclax) block BCL-2, restoring apoptosis in selected CLL/AML

35
New cards

How is extrinsic apoptosis activated, and what limits therapeutic targeting?

FAS/TRAIL ligands activate membrane death receptors and caspases. Tumor microenvironment barriers and decoy receptors limit effectiveness; agonist therapies remain investigational

36
New cards

How does PARP contribute to cell death through different mechanisms?

PARP hyperactivation depletes NAD+, causing parthanatos; PARP inhibition causes persistent DNA breaks and apoptosis in HR-deficient/BRCA-mutated cells

37
New cards

What is necroptosis, and why is it a potential cancer therapy target?

Programmed necrosis mediated by RIPK1/RIPK3/MLKL; activating it may kill apoptosis-resistant tumors. Therapies remain investigational

38
New cards

What is ferroptosis, and how does GPX4 regulate it?

Iron-dependent cell death caused by oxidative damage to membrane polyunsaturated fatty acids. GPX4 detoxifies lipid peroxides; GPX4 inhibitors promote ferroptosis.

39
New cards

What are venetoclax's indications and major clinical considerations?

CLL and selected AML regimens (with hypomethylating agents); major concerns include tumor lysis syndrome (requires ramp-up/monitoring) and CYP3A drug interactions

40
New cards

What are the major steps of autophagy, and how is it initiated?

AMPK activation inhibits mTORC1, activating ULK1 → initiation/nucleation → phagophore elongation → autophagosome-lysosome fusion → cargo degradation.

<p>AMPK activation inhibits mTORC1, activating ULK1 → initiation/nucleation → phagophore elongation → autophagosome-lysosome fusion → cargo degradation.</p>
41
New cards

What is mitophagy, and why is autophagy important in cancer?

Mitophagy selectively removes damaged mitochondria

Autophagy recycles cellular components, supporting tumor survival during hypoxia, nutrient deprivation, and treatment stress

42
New cards

How do mTORC1 and AMPK regulate cell growth and autophagy?

mTORC1 promotes protein synthesis, growth, and survival while suppressing autophagy; nutrient scarcity activates AMPK, inhibiting mTORC1 and promoting autophagy

43
New cards

How are mTOR pathways therapeutically targeted?

mTOR inhibitors (everolimus) suppress growth signaling in selected cancers and can increase autophagy. mTORC1 also regulates S6K1, lipid synthesis, and HIF-1α signaling

44
New cards

How do lysosomes contribute to drug resistance?

They sequester weak-base drugs, reducing cytosolic drug concentrations. TFEB regulates lysosomal biogenesis; potential strategies include lysosomal inhibitors and drug redesign

45
New cards

Why are chloroquine and hydroxychloroquine being investigated in cancer therapy?

They inhibit lysosomal autophagy to reduce treatment-induced tumor survival. Studied with chemotherapy/targeted agents; limitations include low potency, off-target effects, and dosing challenges

46
New cards

What is the rationale for combining autophagy inhibitors with anticancer treatments?

to prevent protective autophagy during treatment stress and resensitize tumors; trials combine inhibitors with chemo/targeted agents while monitoring toxicities

47
New cards

What contributes to tumor heterogeneity and treatment resistance?

differentiation/dedifferentiation, cancer stem cells, and interactions with stromal cells, immune cells, and vasculature

48
New cards

What are the three phases of cancer immunoediting?

elimination: immune cells destroy tumor cell

equilibrium: surviving cells persist under immune pressure

escape: resistant cells evade immunity and proliferate

<p>elimination: immune cells destroy tumor cell</p><p>equilibrium: surviving cells persist under immune pressure</p><p>escape: resistant cells evade immunity and proliferate</p>
49
New cards

What cellular components make up the tumor microenvironment?

cancer cells, cancer-associated fibroblasts (CAFs), immune cells (T/B cells, macrophages, NK cells, dendritic cells), blood/lymphatic vessels, and stromal components

50
New cards

How is tumor angiogenesis targeted, and what toxicities can occur?

VEGF promotes tumor blood vessel formation; bevacizumab blocks VEGF, while VEGFR TKIs inhibit receptor signaling. Toxicities include hypertension, bleeding, and thrombosis

51
New cards

How do immune checkpoint inhibitors treat cancer?

PD-1/PD-L1 and CTLA-4 blockade restores antitumor T-cell activity

ex. pembrolizumab, nivolumab; biomarkers include PD-L1 and MSI status

52
New cards

Why combine immune checkpoint inhibitors with chemotherapy or targeted agents?

combination strategies may enhance antitumor immune responses and overcome immune evasion

53
New cards

How do cancer stem cells (CSCs) contribute to resistance and metastasis?

CSCs (e.g., CD44+, CD133+) resist therapy through quiescence and enhanced DNA repair, promoting tumor recurrence and metastasis; strategies target CSCs or their microenvironment

54
New cards

What are the emerging hallmarks and enabling characteristics of cancer?

deregulated cellular energetics, avoiding immune destruction, tumor-promoting inflammation, and genomic instability/mutations

55
New cards

How does a genetic alteration guide cancer treatment?

genetic alteration → disrupted pathway → cancer phenotype → biomarker testing → targeted therapy/resistance

56
New cards

How does cancer develop through clonal evolution?

normal cells have regulated growth/repair → early mutations increase survival/proliferation → additional alterations promote invasion, metastasis, and resistance

57
New cards

What is the difference between driver and passenger alterations?

Driver: contributes to cancer initiation, growth, or maintenance

Passenger: accumulates without necessarily providing a selective advantag

58
New cards

What are the major types of genetic alterations?

SNV/point mutation: single nucleotide change

Insertion/deletion: added/removed bases (may cause frameshift)

Amplification/deletion: altered gene copy number

Fusion/rearrangement: abnormal gene fusion or regulation

59
New cards

How do epigenetic alterations differ from genetic mutations?

epigenetic changes alter gene expression without changing DNA sequence, often through DNA methylation or histone modifications

60
New cards

How can DNA mutations change protein function and cell behavior?

DNA → RNA → protein → cell behavior

Mutations may cause constitutive activation, loss of function, altered expression/stability, or impaired DNA repair

61
New cards

Do all DNA mutations cause functional changes or require treatment?

No. Some are silent, and not every functional alteration is clinically actionable

62
New cards

What are the three major classes of cancer genes and their functions?

Oncogenes: gain-of-function promotes growth (EGFR, KRAS, BRAF, MYC, HER2)

Tumor suppressors: loss-of-function removes growth restraints (TP53, RB1, APC, PTEN)

DNA repair genes: defects impair repair (BRCA1/2, MLH1, MSH2)

63
New cards

How do proto-oncogenes become oncogenes?

activating mutations, amplifications, or fusions cause excessive signaling → persistent proliferation, survival, or altered differentiation

64
New cards

What are examples of oncogenic alterations, and what determines their clinical relevance?

EGFR activating variants, KRAS G12D, HER2 amplification

Treatment requires identifying the exact alteration, tumor type, and guideline-supported options

65
New cards

How does tumor suppressor loss promote cancer?

loss of cell-cycle checkpoints, growth restraints, or apoptosis allows damaged cells to survive and accumulate mutations

66
New cards

What are the functions of TP53, PTEN, and RB1?

TP53: DNA damage response, arrest, senescence, apoptosis

PTEN: inhibits PI3K signaling

RB1: controls G1 → S transition

67
New cards

How do DNA repair defects create therapeutic vulnerabilities?

repair deficiencies increase mutations/genomic instability and make tumors dependent on remaining repair pathways, which can be therapeutically inhibited

68
New cards

What DNA repair genes are clinically important?

BRCA1/2: homologous recombination repair; mutations may confer PARP inhibitor sensitivity

MLH1/MSH2: mismatch repair; deficiency can cause MSI-high status

69
New cards

What are the major oncogenic signaling pathways and their functions?

RTK → RAS → RAF → MEK → ERK: proliferation/gene expression

PI3K → AKT → mTOR: growth, protein synthesis, survival

p53/RB: cell-cycle checkpoints, DNA damage responses, apoptosis

70
New cards

How do pathway mutations promote uncontrolled cancer growth?

Activating mutations (e.g., RAS) sustain signaling without growth factors; PTEN/p53/RB loss removes inhibitory controls

71
New cards

How do germline and somatic mutations differ?

Germline: present from conception, throughout the body, potentially inherited, increases cancer susceptibility (BRCA1)

Somatic: acquired during life, generally tumor-specific, may drive cancer or predict treatment response (EGFR)

72
New cards

What should be considered when a tumor mutation suggests inherited cancer risk?

confirmatory germline testing and genetic counseling may be appropriate; inherited susceptibility does not guarantee cancer

73
New cards

What are the major hereditary cancer syndromes and associated genes?

BRCA1/2: breast, ovarian, prostate, pancreatic cancer

MLH1/MSH2: Lynch syndrome (colorectal/endometrial)

APC: familial adenomatous polyposis (colorectal)

TP53: Li-Fraumeni (multiple early-onset cancers)

74
New cards

What tests identify tumor alterations?

Tissue biopsy: tumor diagnosis

NGS/PCR/Sanger: DNA/RNA variants and fusions

IHC: protein expression

FISH: amplification/rearrangement

Liquid biopsy: circulating tumor DNA (ctDNA)

75
New cards

What factors must be considered when interpreting molecular testing?

Exact variant, assay limitations, tumor type, treatment history, and clinical evidence. Variants of uncertain significance (VUS) are not proven actionable

76
New cards

How do predictive, prognostic, and actionable biomarkers differ?

Predictive: likelihood of treatment benefit/harm

Prognostic: expected disease outcome

Actionable: supports a clinical decision in a defined context

77
New cards

What are companion diagnostics and tumor-agnostic biomarkers?

Companion diagnostic: test supporting safe/effective therapy use

Tumor-agnostic biomarker: supports treatment across cancer types when approved criteria are met

78
New cards

Which biomarkers guide targeted cancer therapies?

EGFR variants → EGFR TKIs (NSCLC)

HER2 amplification → HER2 therapies

BRAF V600E → BRAF + MEK inhibitors

BRCA1/2 → PARP inhibitors

dMMR/MSI-high → checkpoint inhibitors

KRAS G12C → KRAS G12C inhibitors

79
New cards

Why must biomarker-directed therapy be individualized?

eligibility depends on exact variant, cancer type, previous treatments, current drug labeling, and guidelines

80
New cards

Why can targeted therapy selectively inhibit cancer growth?

some tumors depend on an altered driver protein/pathway; blocking it disrupts signaling, slowing growth or reducing tumor burden

81
New cards

Why do targeted therapy responses vary, and what should pharmacists monitor?

Coexisting mutations, redundant pathways, heterogeneity, drug exposure, and host factors. Monitor indication, testing, adherence, interactions, and adverse effects

82
New cards

How does tumor heterogeneity cause acquired treatment resistance?

therapy eliminates sensitive clones while resistant clones survive and expand, causing disease progression

83
New cards

What are the three major mechanisms of acquired resistance?

secondary mutations reduce drug binding; bypass signaling activates alternative survival pathways; cell-state changes reduce sensitivity without new driver mutations

84
New cards

How can resistance be evaluated after cancer progression?